We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Novel Full-Range Lentivirus Platform from Widely Accessible Core Facility
Product News

Novel Full-Range Lentivirus Platform from Widely Accessible Core Facility

Novel Full-Range Lentivirus Platform from Widely Accessible Core Facility
Product News

Novel Full-Range Lentivirus Platform from Widely Accessible Core Facility


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Novel Full-Range Lentivirus Platform from Widely Accessible Core Facility"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SIRION Biotech has announced its novel lentivirus portfolio for the most sophisticated in vitro applications. Besides its (1) non-toxic transduction enhancer coined LentiBOOST™ , SIRION Biotech offers (2) premade lentivirus vectors and (3) custom services.

The latter allows for all possible modifications and applications ranging from complex and multiple genes expression to TET- inducible all-in-one vectors; lentivirus particles can be ordered directly or as basis for an entire cell line production. The finished cell lines come virus free and ready-to-use.

Genetic modification is a prerequisite for today's target research and cell based assay screening for compound development.

Viral vectors work both in vitro and in vivo, are versatile and warrant high gene delivery rates: The viruses' own infection machinery is being used to transport genetic material into the host cells.

Several viral vector platforms are in use: lentivirus lends itself to stable gene modifications as opposed to transient modifications like with adenovirus (AV) and adeno-associated virus (AAV).

Specialized service providers like SIRION Biotech are able to provide custom lentivirus and the resulting stable cell pools within a matter of weeks, premade lentiviral particles can be shipped literally over night.

The availability of such focused services allows for faster and more reliable research.

Viral vector technologies are applicable from drug discovery to food sciences and cosmetics developments.

Advertisement